Abemaciclib + Fulvestrant + Standard Chemotherapy
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Aug 14, 2019 → Aug 11, 2020
NCT ID
NCT04031885About Abemaciclib + Fulvestrant + Standard Chemotherapy
Abemaciclib + Fulvestrant + Standard Chemotherapy is a approved stage product being developed by Eli Lilly for Metastatic Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04031885. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04031885 | Approved | Terminated |
Competing Products
20 competing products in Metastatic Breast Cancer